Employees: 1,412
Size Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $602M, the 3234th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥37.61 on 18 Nov 2026.
Performance Over six months the shares fell 37.8%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +2.6%); the operating margin is -29.9% (peer median 4.4%).
Valuation It trades at 54.0× forward earnings against a peer median of 11.4× (2nd most expensive of 8).
Capital Return on invested capital runs 10.2 points below its cost of capital (8.6% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥618M | CN¥678M | CN¥802M | CN¥1.02B | CN¥607M |
| Revenue growth | — | -15% | -21% | +68% | — |
| Gross profit | CN¥260M | CN¥186M | CN¥330M | CN¥614M | CN¥381M |
| EBITDA | n/a | CN¥74.7M | CN¥101M | CN¥353M | CN¥197M |
| Net income | -CN¥178M | -CN¥90.4M | -CN¥52.7M | CN¥272M | CN¥194M |
| Free cash flow | -CN¥71.3M | -CN¥250M | -CN¥590M | -CN¥598M | -CN¥332M |
| Capital expenditure | CN¥85.8M | CN¥97.9M | CN¥395M | CN¥689M | CN¥592M |
| Total debt | CN¥950M | CN¥884M | CN¥724M | CN¥474M | CN¥36.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301096.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.9% | -11.8% | 7th lowest of 20 |
| 6-month return | -37.8% | -26.6% | 8th lowest of 20 |
| Distance from 52-week high | -51.3% | -43.9% | 9th lowest of 20 |
| Revenue growth (TTM) | +4.7% | +2.6% | 6th highest of 15 |
| Operating margin | -29.9% | 4.4% | 3rd lowest of 14 |
| Forward P/E | 54.0× | 11.4× | 2nd most expensive of 8 |
| ROIC minus cost of capital | -10.2 pp | -4.0 pp | 4th lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 54.0× | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | n/a | -0.6% | -1.6% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 6.7× | -6.2% | +6.5% |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 11.4× | -6.6% | +5.4% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | n/a | -1.0% | -17.9% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | n/a | 10.1% | +2.1% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | n/a | 10.9% | -5.9% |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 83.1× | n/a | n/a |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 10.2× | -8.7% | +8.8% |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | n/a | n/a | n/a |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 26.8× | 20.9% | +21.9% |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 53.6× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | n/a | n/a | n/a |